financetom
Business
financetom
/
Business
/
JPMorgan veteran Andy O'Brien to retire after 40-year stint at Wall Street giant
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
JPMorgan veteran Andy O'Brien to retire after 40-year stint at Wall Street giant
Jun 3, 2025 12:22 PM

(Reuters) -Andy O'Brien, the global head of loan capital strategy at JPMorgan Chase ( JPM ), is set to retire at the end of 2025 after 40 years at the largest U.S. lender, according to an internal memo seen by Reuters on Tuesday.

In his current role, O'Brien has been responsible for overseeing the lending portfolio across JPMorgan's ( JPM ) global corporate and investment banking businesses.

Over the years, O'Brien has held various leadership roles within JPMorgan ( JPM ), including as the global co-head of debt capital markets.

"Andy has been pivotal in developing our world-leading debt franchise over the span of his remarkable career," Bregje de Best and James Roddy, co-heads of global corporate banking at J.P. Morgan said in the memo.

Throughout his time at JPMorgan ( JPM ), O'Brien led several high-profile financings, including the $61 billion bridge loan to finance Verizon's 2013 acquisition of Vodafone's wireless unit.

During the 2008 global financial crisis, O'Brien helped the U.S. government structure its rescue financing of insurer AIG.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Alterity Therapeutics Says ATH434 Showed Slowing of Clinical Progression in Phase 2 Multiple System Atrophy Study; Shares Up
Alterity Therapeutics Says ATH434 Showed Slowing of Clinical Progression in Phase 2 Multiple System Atrophy Study; Shares Up
Jan 30, 2025
09:39 AM EST, 01/30/2025 (MT Newswires) -- Alterity Therapeutics ( ATHE ) shares were sharply higher Thursday morning after the company said that its ATH434 lead candidate demonstrated 48% slowing of clinical progression in a phase 2 clinical trial in patients with early-stage multiple system atrophy. The result was achieved at the 50 mg dose at week 52 when compared...
Wells Fargo Names Fernando Rivas Sole CEO of CIB Unit as Jon Weiss Steps Down
Wells Fargo Names Fernando Rivas Sole CEO of CIB Unit as Jon Weiss Steps Down
Jan 30, 2025
09:38 AM EST, 01/30/2025 (MT Newswires) -- Wells Fargo ( WFC ) said Thursday that Fernando Rivas will become the sole chief executive of its Corporate & Investment Banking, or CIB, division as Jon Weiss steps down immediately and plans to retire on June 1. Weiss has been with the company for about 20 years, Wells Fargo ( WFC )...
Novo Nordisk's new CagriSema obesity drug trial to begin on Feb. 10, clinicaltrials.gov entry shows
Novo Nordisk's new CagriSema obesity drug trial to begin on Feb. 10, clinicaltrials.gov entry shows
Jan 30, 2025
LONDON, Jan 30 (Reuters) - Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a www.clinicaltrials.gov entry. The Danish drugmaker last month revealed disappointing results in a late-stage trial of CagriSema, wiping as much as $125 billion off its market value. It said then that it would initiate a...
Baker Hughes Awarded LNG Contract From Venture Global
Baker Hughes Awarded LNG Contract From Venture Global
Jan 30, 2025
09:36 AM EST, 01/30/2025 (MT Newswires) -- Baker Hughes ( BKR ) said Thursday that it has been awarded a contract to provide a liquefied natural gas system and power island to support Venture Global's ( VG ) LNG projects in the US. Baker Hughes ( BKR ) also said it signed a multi-year services frame agreement to provide maintenance,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved